LOTUSEYE112.50

Lotus Eye Hospital and Institute Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹234 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY21
30/09/2020
Revenue from Operations7.2
Other Income0.2
Total Income7.4
Expenses
+ Cost of Materials Consumed1.1
+ Purchases of Stock-in-Trade1.1
+ Changes in Inventories0.0
+ Employee Benefit Expense1.6
+ Finance Costs0.0
+ Depreciation & Amortisation0.6
+ Other Expenses3.0
Total Expenses7.4
EBITDA0.4
EBIT-0.2
Profit
PBT before Exceptional Items-0.0
+ Exceptional Items0.1
Pretax Income0.1
+ Deferred Tax-0.0
Tax Expense-0.0
Net Income0.1
+ Net Income — Continuing Ops0.1
+ Other Comprehensive Income0.0
Total Comprehensive Income0.1
Per Share
Basic EPS0.04
Diluted EPS0.04
Per Share — as-filed variants
Basic EPS — Continuing Operations0.04
Diluted EPS — Continuing Operations0.04
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit5.0
Gross Margin %69.16
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-0.0
− Exceptional Items (reconciliation)0.1
Net Income Adj (tax-effected)-0.0
EPS Adj-0.00
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.00
Paid Up Equity Capital20.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q2 FY21 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.